# Pizarra — PT-pseudo_37d8ae9b27f1 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_37d8ae9b27f1
Task: 1

Encounter: Urology - outpatient on 18 Jan 2025.
Referrer: Dr. S. de Vries (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 4.8 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.053 ng/mL²
  - PSA velocity: 0.39 ng/mL/yr
  - Prior PSA: 4.7 ng/mL
  - Prostate volume: 90.82 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.46945655 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 4.8 ng/mL. PI-RADS 4. PSAD 0.05. Prostate volume 91 mL. csPCa 0.47.

Vitals: weight 76 kg, height 180 cm, BMI 23.5, BP 120/76 mmHg, HR 79 bpm. Smoking: Non-smoker.

Chief complaint: Clinical attention sought due to a previous prostate cancer diagnosis coupled with a recent serum PSA rise to 4.8 ng/mL.

History: At sixty-seven years of age, this widowed patient has a documented history of a prior positive biopsy confirming low-grade malignancy. Initial evaluation for an elevated PSA occurred in 2022. He experiences moderate lower urinary tract symptoms, scoring 16 on the IPSS questionnaire, dominated by nocturia and a diminished urinary stream that have not progressed recently. Occupational background includes work as a retired mechanical engineer. He resides independently. Lifestyle factors include being a Non-smoker, consuming six alcoholic units weekly, and participating in weekly swimming sessions. Past medical encounters involve standard audiology and vascular surgery visits for unrelated aging processes, with no other significant comorbidities or active medications reported. He explicitly denies bone discomfort, haematuria, or constitutional complaints.

Physical examination: Normal DRE: Symmetrically enlarged gland exhibiting a uniform, smooth consistency without focal hardening or asymmetry. Systemic inspection shows stable hemodynamic parameters, clear lung fields, and absence of peripheral edema or palpable lymph nodes.

Patient info: retired mechanical engineer; Widowed; Lives alone.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 6 units / week; exercise Swimming 1x/week; IPSS score: 16/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test; Vascular surgery — varicose veins consult.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.64 +/- 0.19   (95% CI 0.25-0.94)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 7.1 effective neighbours out of 10; 4 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=3.0, psa=4.8, age=67.0, psad=0.053, dre_ord=0.0, vol=90.82, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's prior positive biopsy status (which suggests a known low-grade malignancy) against the current PI-RADS 4 score and the rising PSA velocity (0.39 ng/mL/yr). It also could not incorporate the specific details from the retrieved documents, such as the full mpMRI report findings or the PSA history trend, which are crucial for contextualizing the current findings.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests BIOPSY with a wide interval (0.64 +/- 0.19), indicating it is in the 'discuss' tier. A failure mode is the contradiction between the prior positive biopsy and the current PI-RADS 4 score, which might suggest surveillance is appropriate, despite the rising PSA. Another failure mode is the lack of information regarding the PSA trend or the full MRI report, meaning the prior cannot assess the significance of the PSA velocity (0.39 ng/mL/yr) relative to the prior PSA of 4.7 ng/mL.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report suggests clinically insignificant findings despite PI-RADS 4, it would argue against biopsy.
  <document> PSA history (trend) -> If the trend is stable or decreasing, it would temper the urgency suggested by the current PSA of 4.8 ng/mL.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the initial diagnosis or follow-up plan.
  <document> laboratory results (full panel) -> This could reveal other markers that influence the risk stratification.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_37d8ae9b27f1", "radiology_report": "Subject: Multiparametric MRI Prostate | Radboudumc\nDate: 11 January 2021\n\nClinical context: Serum PSA currently measures 4.8 ng/mL, with a prior PI-RADS 4 classification.\n\nFINDINGS:\nGlandular dimensions total 90.82 mL. T2-weighted imaging isolates a discrete hypointense region within the left peripheral zone, spanning the mid-gland to the base, spanning roughly 14 by 9 mm. High b-value diffusion sequences show marked restriction, mirrored by hypointensity on the apparent diffusion coefficient map. Post-contrast dynamics highlight early, localized enhancement against the background peripheral tissue. The capsule remains intact without extraprostatic spread, seminal vesicle involvement, or nodal abnormalities.\n\nIMPRESSION:\nPI-RADS 4 lesion in the left peripheral zone.\nProstate volume 90.82 mL yielding a PSA density of 0.053 ng/mL/mL.\ncsPCa predicted probability 0.46945655"}

  **psa_trend**
  {"case_id": "PT-pseudo_37d8ae9b27f1", "psa_trend": [{"date": "Aug 2022", "val": 3.6}, {"date": "May 2023", "val": 1.2}, {"date": "Mar 2024", "val": 3.1}, {"date": "Jan 2025", "val": 4.8}]}

  **previous_notes**
  {"case_id": "PT-pseudo_37d8ae9b27f1", "previous_notes": [{"date": "23 May 2024", "author": "Dr. S. de Vries (GP)", "text": "28 July 2023 - Dr. S. de Vries (GP): Clinical review focused on the evolving PSA profile. The latest measurement registers at 4.1 ng/mL, reflecting a steady increase from the initial baseline. The clinical team will maintain standard surveillance protocols."}, {"date": "28 Jul 2023", "author": "Dr. S. de Vries (GP)", "text": "23 May 2024 - Dr. S. de Vries (GP): Laboratory analysis demonstrates a subsequent PSA increase to 4.7 ng/mL. Considering the documented history of a previously positive biopsy alongside this sustained elevation, a urology re-evaluation was initiated. The patient received notification regarding the outpatient appointment."}]}

  **laboratory_results**
  {"case_id": "PT-pseudo_37d8ae9b27f1", "laboratory_results": [{"name": "PSA", "val": "4.8 ng/mL", "date": "12 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "1.20 ng/mL", "date": "12 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "25%", "date": "12 Dec 2024", "flag": ""}, {"name": "Haemoglobin", "val": "14.8 g/dL", "date": "12 Dec 2024", "flag": ""}, {"name": "WBC", "val": "8.6 x10^9/L", "date": "12 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "210 x10^9/L", "date": "12 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "104 umol/L", "date": "12 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "12 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "13.2 nmol/L", "date": "12 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "50 U/L", "date": "12 Dec 2024", "flag": ""}, {"name": "LDH", "val": "193 U/L", "date": "12 Dec 2024", "flag": ""}]}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - PI-RADS 4 lesion in the left peripheral zone
  - PSA velocity of 0.39 ng/mL/yr (rising trend)
  - PSA has risen from 4.7 ng/mL (last recorded prior to current 4.8 ng/mL)

  AGAINST sampling this patient now:
  - Prior biopsy was positive (suggesting known low-grade malignancy)
  - DRE findings are Normal

WHERE THIS LEANS
  The evidence suggests a need for further investigation due to the PI-RADS 4 finding and rising PSA velocity, which aligns with the statistical prior suggesting biopsy. However, the prior positive biopsy and normal DRE argue against immediate aggressive intervention, leaning towards continued surveillance unless the MRI findings are deemed highly concerning.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: NO BIOPSY   (confidence: borderline)

Deferring biopsy is recommended because the patient has a prior positive biopsy, which argues against immediate intervention, despite the current PI-RADS 4 finding. The decision is complicated by the rising PSA velocity of 0.39 ng/mL/yr and the current PSA of 4.8 ng/mL. The evidence suggests continued surveillance is appropriate given the known history, although the PI-RADS 4 lesion is a significant finding.

Variables that carried weight: bx=decisive, age=noted, dre=noted, psa=important, vol=noted, psad=noted, pirads=important
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
